Long-term results of amitriptyline treatment for interstitial cystitis
Monitor with CGM for real-time insulin response
Morris A Phase 1-2 Study of HLD-0915 in People With Advanced Prostate Cancer A Phase 1b Study of Xaluritamig in People With Castration-Sensitive Prostate Cancer A Phase 1b/2 Study of Tinengotinib (TT-00420) Plus Standard Treatments in People With Advanced Prostate Cancer A Phase 2 Study of Ac-225 Rosopatamab Tetraxetan (CONVO1-Alpha) in People With Advanced Prostate Cancer A Phase 2 Study of Tarlatamab for People With Advanced Prostate Cancer A Phase 3 Study Comparing Lutetium Vipivotide Tetraxetan (AAA617, Pluvicto) With Observation in People with Prostate-Specific Membrane Antigen (PSMA)-Positive Oligometastatic Prostate Cancer A Phase 3 Study of Xaluritamig Versus Cabazitaxel or Second Androgen Receptor-Directed Therapy for People With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) with Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3) A Phase I Study of AMG 509 in Men with Advanced Prostate Cancer A Phase I Study of ORIC-944 to Treat Metastatic Prostate Cancer A Study of AZD0516 in People With Prostate Cancer A Study of AZD6621 in People With Prostate Cancer A Study of Stereotactic Body Radiotherapy (SBRT) and Pluvicto (177Lu-PSMA-617) in People With Prostate Cancer Testing different dosing schedules of the anti-cancer drug, Lutetium-177-PSMA (Pluvicto), and its effect on patients with advanced prostate cancer Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer
Any cat peptide supplement should avoid drug-like promises and fit into a feeding plan without displacing complete nutrition
Human Cell 38 , 107 (2025)
While other dopamine agonists are successful at controlling symptoms of PD early on in the onset of the disease, L-DOPA is the most effective pharmaceutical at helping to improve QoL, especially once symptoms become more unmanageable with other anti-parkinsonian medications
